Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350863 | 1.00 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4DHODHFABP4 | |
| SCHEMBL1752156 | 1.00 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4DHODHFABP4 | |
| SCHEMBL1751614 | 1.00 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4DHODHFABP4 | |
| SCHEMBL4350872 | 1.00 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4DHODHFABP4 | |
| SCHEMBL1752157 | 1.00 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4DHODHFABP4 | |
| SCHEMBL1751726 | 0.96 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4DHODHFABP4 | |
| SCHEMBL10384372 | 0.87 | SLC6A2 (0.50) | SLC6A3SLC6A2SLC6A4DHODHFABP4 | |
| SCHEMBL4350867 | 0.85 | SLC6A3 (0.71) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17972851 | 0.84 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4FGF23PTGS2 | |
| SCHEMBL6692371 | 0.84 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4DHODHFGF23 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | claimed |
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | claimed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | claimed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | disclosed |
| EP-2029541-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007113155-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC Β-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | AHR, AR, CYP8B1 | SLC6A3 2693/4885SLC6A2 2378/4885SLC6A4 2893/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | SLC6A3 2337/4885SLC6A2 2332/4885SLC6A4 3061/4885 |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | AHR, CYP8B1, ADRA2C | SLC6A3 2337/4885SLC6A2 2332/4885SLC6A4 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.